(AJ91) DocCheck - Ratings and Ratios
Portal, Advertising, Research, Strategies, Investments
Description: AJ91 DocCheck
DocCheck AG is a European healthcare marketing and e-commerce specialist, providing a multifaceted platform for industry stakeholders to connect, advertise, and conduct market research. The companys flagship DocCheck portal serves as a hub for information exchange, while its comprehensive suite of services includes online advertising, market studies, and tailored communication strategies for healthcare and B2B clients. With a history dating back to 1990, DocCheck AG has established itself as a key player in the healthcare technology sector, headquartered in Cologne, Germany.
From a market perspective, DocCheck AGs position within the Health Care Technology sub-industry is noteworthy, with a market capitalization of €56.32 million. Its return on equity stands at 20.03%, indicating a robust ability to generate profits from shareholder equity. The companys P/E ratio of 23.13 suggests a moderate valuation relative to its earnings, although the absence of a forward P/E ratio complicates future earnings expectations.
Technically, the stock has demonstrated a strong upward trend, with its current price of €12.00 representing a 52-week high. The stocks short-term and long-term moving averages (SMA20: €10.80, SMA50: €10.28, SMA200: €8.88) indicate a sustained bullish momentum, with the stock price consistently outperforming its historical averages. The average true range (ATR) of €0.33, or 2.76%, suggests moderate daily price volatility.
By synthesizing the available technical and fundamental data, a forecast can be derived. Given the stocks bullish trend, robust return on equity, and moderate valuation, a reasonable expectation is that DocCheck AGs stock will continue to appreciate in the short to medium term. A potential target price could be €15.00, representing a 25% increase from the current price, driven by sustained demand for healthcare technology services and the companys established market position. However, this forecast is contingent upon the absence of significant market downturns or unforeseen disruptions to the healthcare technology sector.
AJ91 Stock Overview
| Market Cap in USD | 69m |
| Sub-Industry | Health Care Technology |
| IPO / Inception |
AJ91 Stock Ratings
| Growth Rating | 25.8% |
| Fundamental | 74.2% |
| Dividend Rating | 52.5% |
| Return 12m vs S&P 500 | 45.2% |
| Analyst Rating | - |
AJ91 Dividends
| Dividend Yield 12m | 7.20% |
| Yield on Cost 5y | 7.19% |
| Annual Growth 5y | 37.97% |
| Payout Consistency | 79.2% |
| Payout Ratio | 48.1% |
AJ91 Growth Ratios
| Growth Correlation 3m | -20.6% |
| Growth Correlation 12m | 86.5% |
| Growth Correlation 5y | -72.9% |
| CAGR 5y | 3.70% |
| CAGR/Max DD 5y | 0.05 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | 41.43 |
| Beta | 0.472 |
| Volatility | 29.37% |
| Current Volume | 0k |
| Average Volume 20d | 0.6k |
| Stop Loss | 11.7 (-3.3%) |
| Signal | -1.99 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (7.55m TTM) > 0 and > 6% of Revenue (6% = 6.43m TTM) |
| FCFTA 0.20 (>2.0%) and ΔFCFTA 18.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.34% (prev 20.94%; Δ 1.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 15.3m > Net Income 7.55m (YES >=105%, WARN >=100%) |
| Net Debt (-12.0m) to EBITDA (17.3m) ratio: -0.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.07m) change vs 12m ago 0.20% (target <= -2.0% for YES) |
| Gross Margin 21.46% (prev 24.42%; Δ -2.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 182.0% (prev 157.5%; Δ 24.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 64.25 (EBITDA TTM 17.3m / Interest Expense TTM 168.7k) >= 6 (WARN >= 3) |
Altman Z'' 6.48
| (A) 0.39 = (Total Current Assets 37.7m - Total Current Liabilities 13.8m) / Total Assets 60.9m |
| (B) 0.41 = Retained Earnings (Balance) 24.7m / Total Assets 60.9m |
| (C) 0.18 = EBIT TTM 10.8m / Avg Total Assets 58.9m |
| (D) 1.28 = Book Value of Equity 26.6m / Total Liabilities 20.8m |
| Total Rating: 6.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.24
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 28.62% = 5.0 |
| 3. FCF Margin 11.55% = 2.89 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.05 = 2.50 |
| 6. ROIC - WACC 12.41% = 12.50 |
| 7. RoE 20.03% = 1.67 |
| 8. Rev. Trend -42.54% = -2.13 |
| 9. Rev. CAGR -18.23% = -2.50 |
| 10. EPS Trend -54.00% = -1.35 |
| 11. EPS CAGR 11.62% = 1.16 |
What is the price of AJ91 shares?
Over the past week, the price has changed by +4.31%, over one month by -2.42%, over three months by +6.61% and over the past year by +70.86%.
Is DocCheck a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AJ91 is around 13.01 EUR . This means that AJ91 is currently overvalued and has a potential downside of 7.52%.
Is AJ91 a buy, sell or hold?
What are the forecasts/targets for the AJ91 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 14.4 | 19% |
AJ91 Fundamental Data Overview
Market Cap EUR = 59.4m (59.4m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 17.0m EUR (last quarter)
P/E Trailing = 11.25
P/S = 1.1037
P/B = 1.4938
Beta = 0.772
Revenue TTM = 107.2m EUR
EBIT TTM = 10.8m EUR
EBITDA TTM = 17.3m EUR
Long Term Debt = unknown (0.0)
Short Term Debt = 911.0k EUR (from shortTermDebt, last quarter)
Debt = 911.0k EUR (Calculated: Short Term 911.0k + Long Term 0.0)
Net Debt = -12.0m EUR (from netDebt column, last quarter)
Enterprise Value = 43.3m EUR (59.4m + Debt 911.0k - CCE 17.0m)
Interest Coverage Ratio = 64.25 (Ebit TTM 10.8m / Interest Expense TTM 168.7k)
FCF Yield = 28.62% (FCF TTM 12.4m / Enterprise Value 43.3m)
FCF Margin = 11.55% (FCF TTM 12.4m / Revenue TTM 107.2m)
Net Margin = 7.05% (Net Income TTM 7.55m / Revenue TTM 107.2m)
Gross Margin = 21.46% ((Revenue TTM 107.2m - Cost of Revenue TTM 84.2m) / Revenue TTM)
Tobins Q-Ratio = 1.63 (Enterprise Value 43.3m / Book Value Of Equity 26.6m)
Interest Expense / Debt = 4.61% (Interest Expense 42.0k / Debt 911.0k)
Taxrate = 30.09% (from yearly Income Tax Expense: 2.27m / 7.56m)
NOPAT = 7.58m (EBIT 10.8m * (1 - 30.09%))
Current Ratio = 2.74 (Total Current Assets 37.7m / Total Current Liabilities 13.8m)
Debt / Equity = 0.02 (Debt 911.0k / last Quarter total Stockholder Equity 40.1m)
Debt / EBITDA = 0.05 (Net Debt -12.0m / EBITDA 17.3m)
Debt / FCF = 0.07 (Debt 911.0k / FCF TTM 12.4m)
Total Stockholder Equity = 37.7m (last 4 quarters mean)
RoA = 12.41% (Net Income 7.55m, Total Assets 60.9m )
RoE = 20.03% (Net Income TTM 7.55m / Total Stockholder Equity 37.7m)
RoCE = 28.73% (Ebit 10.8m / (Equity 37.7m + L.T.Debt 0.0))
RoIC = 20.09% (NOPAT 7.58m / Invested Capital 37.7m)
WACC = 7.68% (E(59.4m)/V(60.3m) * Re(7.75%)) + (D(911.0k)/V(60.3m) * Rd(4.61%) * (1-Tc(0.30)))
Shares Correlation 5-Years: 80.0 | Cagr: 0.11%
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈7.95m ; Y1≈9.81m ; Y5≈16.7m
Fair Price DCF = 56.09 (DCF Value 284.6m / Shares Outstanding 5.07m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: -42.54 | Revenue CAGR: -18.23%
Rev Growth-of-Growth: 76.89
EPS Correlation: -54.00 | EPS CAGR: 11.62%
EPS Growth-of-Growth: 48.46